中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.014 seconds)

    ANALYSIS/DIAGNOSIS METHOD UTILIZING RNA MODIFICATION
    2.
    发明公开
    ANALYSIS/DIAGNOSIS METHOD UTILIZING RNA MODIFICATION 审中-公开

    公开(公告)号：US20230175066A1

    公开(公告)日：2023-06-08

    申请号：US16971604

    申请日：2019-02-21

    Applicant: OSAKA UNIVERSITY

    Inventor： Hideshi Ishii ,  Masamitsu Konno ,  Masaki Mori

    IPC: C12Q1/6886

    CPC classification number: C12Q1/6886 ,  C12Q1/6827 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/178

    Abstract: The present application provides a novel method for analyzing a biological condition or a medical condition. It is now found that information about the modification of RNA can be used for the analysis of a biological condition or a medical condition. On the basis of this finding, the present invention provides a novel method for analyzing a biological condition or a medical condition. According to the present invention, it becomes possible to analyze various biological conditions or medical conditions including diseases, and it also becomes possible to satisfactorily predict cancer (e.g., pancreatic cancer, colorectal cancer, stomach cancer) in an early stage.

    Novel Antitumor Agent and Method For Screening Same
    5.
    发明申请
    Novel Antitumor Agent and Method For Screening Same 审中-公开
    新型抗肿瘤剂及其筛选方法

    公开(公告)号：US20140377768A1

    公开(公告)日：2014-12-25

    申请号：US14374907

    申请日：2013-01-28

    Applicant: Osaka University

    Inventor： Masaru Ishii ,  Yoshinori Kagawa ,  Masaki Mori ,  Hideshi Ishii

    IPC: C12N15/113 ,  C12Q1/68

    CPC classification number: C12N15/113 ,  A61K31/7115 ,  C12N2310/11 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/5011 ,  G01N2333/726 ,  G01N2500/04 ,  G01N2800/7028

    Abstract: The present invention provides a novel antitumor agent that acts through a novel mechanism. The novel antitumor agent contains as an active ingredient a substance capable of inhibiting a cell cycle-dependent Rho GTPase activating protein (RhoGAP). The RhoGAP is cell cycle-dependent and plays an important role in a process through which cancer cells acquire invasive capacity and/or metastatic capacity. The invasion and/or metastasis of cancer cells can be controlled by targeting the RhoGAP. Examples of the substance capable of inhibiting a cell cycle-dependent RhoGAP include an antisense oligonucleotide against a gene encoding the RhoGAP and an oligonucleotide that induces RNA interference of the gene. As the oligonucleotide, one containing an artificial nucleic acid such as BNA is preferred because of its excellent stability. The present invention also provides a screening method including selecting an antitumor agent capable of suppressing cancer cell invasion and/or metastasis through a novel mechanism. The screening method is a screening method for a novel antitumor agent, including selecting a substance capable of inhibiting a cell cycle-dependent Rho GTPase activating protein.

    Abstract translation: 本发明提供一种通过新颖的机理起作用的新型抗肿瘤剂。 新型抗肿瘤剂含有作为活性成分的能够抑制细胞周期依赖性Rho GTPase激活蛋白（RhoGAP）的物质。 RhoGAP是细胞周期依赖性的，并且在癌细胞获得侵袭能力和/或转移能力的过程中起重要作用。 可以通过靶向RhoGAP来控制癌细胞的侵袭和/或转移。 能够抑制细胞周期依赖性RhoGAP的物质的实例包括针对编码RhoGAP的基因的反义寡核苷酸和诱导该基因的RNA干扰的寡核苷酸。 作为寡核苷酸，由于其优异的稳定性，因此优选含有人造核酸如BNA的寡核苷酸。 本发明还提供一种筛选方法，其包括通过新的机理选择能够抑制癌细胞侵袭和/或转移的抗肿瘤剂。 筛选方法是新型​​抗肿瘤剂的筛选方法，包括选择能够抑制细胞周期依赖性Rho GTPase激活蛋白的物质。

    MULTIPLEX COLON CANCER MARKER PANEL
    8.
    发明申请
    MULTIPLEX COLON CANCER MARKER PANEL 审中-公开
    多功能殖民地癌症标志物面板

    公开(公告)号：US20130165340A1

    公开(公告)日：2013-06-27

    申请号：US13723133

    申请日：2012-12-20

    Applicant: SHIMADZU CORPORATION ,  OSAKA UNIVERSITY

    Inventor： Makoto Watanabe ,  Eiichi Matsuo ,  Naoki Kaneko ,  Toshiya Matsubara ,  Osamu Nishimura ,  Masaki Mori ,  Hideo Matsuda ,  Shigeto Seno ,  Ichiro Takemasa

    IPC: G01N33/68

    CPC classification number: G01N33/57419 ,  G01N33/6893

    Abstract: The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2.A method for analyzing colon cancer markers using multiplex colon cancer marker panel.

    Abstract translation: 本发明提供了基于统计知识的结肠癌标志物的特异性组合，其能够在保持高特异性的同时检测较早数量的结肠癌患者。 包括癌胚抗原相关细胞粘附分子5，碳水化合物抗原19-9，半乳凝素-4，APEX核酸酶和肌动蛋白相关蛋白2的五个结肠癌标志物的组合的多重结肠癌标志物。2.一种分析结肠癌标志物的方法 使用多重结肠癌标记物。

Patent Agency Ranking